Both authors contributed equally to this work.
Histopathological atlas and proposed classification for melanocytic lesions in Tyr::NRasQ61K; Cdkn2a−/− transgenic mice
Article first published online: 30 MAY 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Pigment Cell & Melanoma Research
Volume 26, Issue 5, pages 735–742, September 2013
How to Cite
Campagne, C., Reyes-Gomez, E., Battistella, M., Bernex, F., Château-Joubert, S., Huet, H., Beermann, F., Aubin-Houzelstein, G. and Egidy, G. (2013), Histopathological atlas and proposed classification for melanocytic lesions in Tyr::NRasQ61K; Cdkn2a−/− transgenic mice. Pigment Cell & Melanoma Research, 26: 735–742. doi: 10.1111/pcmr.12115
- Issue published online: 23 AUG 2013
- Article first published online: 30 MAY 2013
- Accepted manuscript online: 4 MAY 2013 11:34AM EST
- Institut National de la Recherche Agronomique
- French Ministry of Research
In humans, cutaneous melanoma (CM) is the deadliest cutaneous cancer. In recent years, the identification of recurrent mutations in CM allowed partial understanding of the molecular pathogenesis of CM. Mutations in the proto-oncogene NRAS occur in 18% to 20% of CM and are particularly frequent in the nodular subtype (Lee et al., 2011). NRAS mutations mostly occur in codon 61 of exon 2 where a lysine replaces a glutamine (Q61K), leading to a constitutively activated NRAS protein that promotes both proliferation and survival of melanoma cells (Ellerhorst et al., 2011; Lee et al., 2011). Interestingly, NRAS mutations are associated with distinct clinical and pathological features such as worse prognosis and shorter melanoma-specific survival (Devitt et al., 2011).
Inactivation of the CDKN2A locus, which encodes the two tumor suppressor proteins p16INK4A and p14ARF, is also frequently encountered in CM (Serrano et al., 1996) and most often occurs through deletion (Funk et al., 1998). Both mono- and bi-allelic deletions are found and are associated with shorter median survival (Grafstrom et al., 2005).
The need for a reliable model of human CM led to the generation of transgenic mice combining both dominant-active NRAS targeted to the melanocyte lineage (Tyr::NRasQ61K) and partial or total deletion of the Cdkn2a locus. These Tyr::NRasQ61K; Cdkn2a−/+ and Tyr::NRasQ61K; Cdkn2a−/− mice spontaneously develop metastasizing CM (Ackermann et al., 2005). Over the years, this model gained wide popularity in preclinical studies investigating the links between causative mutations, tumor progression and response to new therapeutics. However, to date, histopathological description of this model remains scarce and the terminology quite inconsistent among authors. Accurate pathological description and classification of melanocytic lesions (ML) is essential to evaluate animal models of melanoma (Sellers and Ward, 2012; Walker et al., 2011). Here, we propose a detailed histopathological atlas and classification of melanocytic lesions encountered in Tyr::NRasQ61K; Cdkn2a−/− or Cdkn2a−/+ transgenic mice along with their main microscopic features, with a particular emphasis on cutaneous ML. Our data highlight the histopathological specificity of melanoma in comparison to the other ML encountered in this model. Comparison to human ML is briefly discussed.
Melanocytic lesions in Tyr::NRasQ61K; Cdkn2a−/− or Cdkn2a−/+ mice were commonly observed in the skin, lymph nodes, brain, eyes, and lungs. Infrequent sites included liver, spleen, heart, harderian gland and epididymis. The most common lesions and their frequency in the 35 necropsied mice are summarized in Table S1. Types of lesions and incidence did not vary between sexes. Gross features are summarized in Figure S1.
Primary cutaneous ML were invariably present in the skin and were observed on gross examination as early as 2 months of age (Figures 1 and 2; Table 1). At that time, cutaneous thickness progressively increased and tousled, disarranged hairs arose giving a dull appearance to the mouse fur (Figure S1a-c). The distribution of ML ranged from patchy, with well-individualized lesions, to continuous when ML were numerous and coalesced. The type, number, size, distribution and density of ML could vary among different samples from the same animal. Overall, microscopic small cutaneous ML occurred all over the body, while no gross lesion was found on ventral skin.
|Type A lesion||Type B lesion||Type C lesion||Type D lesion|
Usually < 200 μm (not grossly visible)
May be composed of only few melanocytes
|Usually > 200 μm but not grossly visible|| |
Usually > 200 μm (usually grossly visible)
May coalesce horizontally and form plaques
|Usually > 2 mm (grossly visible)|
|Location||Dermis, usually in the vicinity of hair follicles||Dermis, usually in the vicinity of hair follicles|| |
Usually upper and mid dermis
Large lesions may occupy entire dermis
|Usually dermis and hypodermis|
Ill-defined contours that blend in the dermis
Usually well-defined contours
Roughly nodular or piriform shape
Usually ill-defined contours
Rarely, cells invade the epidermis
Forms nodule or plaques
Usually well-defined contours
|Cellular density||Low: cells separated by collagen bundles||High: cells are tightly packed with few to no collagen bundles||High: cells are tightly packed with few to no collagen bundles||High with delicate stroma|
|Cell shape|| |
Spindle to epithelioid
Moderate to low NCR
Spindle to epithelioid
Moderate to low NCR
Small with fine/dusty chromatin
Round with fine chromatin
Round with clear chromatin
Round and large nucleolus
Round with clear chromatin
Round and large nucleolus
|Atypias||Absent||Absent or subtle||Moderate||Moderate to high|
|Mitosis||Absent||Absent||≤1 per 10 HPF||≥5 per 10 HPF|
|Pigment||Abundant||Abundant to moderate||Usually scarse in upper-dermis cells, moderate to abundant in lower dermis cells||Usually low to absent but some lesions well-pigmented|
|Vessels||Absent||Small vessels may be present||Small vessels usually well discernable||Abundant with pseudorosettes formation|
Ulceration is rare
Necrosis is absent
|May be present|
Microscopically, ML encompassed a morphological spectrum in which we identified four main types of ML. In such a spectrum, a type was defined only when significantly distinctive morphological features were observed and could be relevant for the model. Occasionally, some lesions could not be assigned to a single type due to intermediate features.
In terms of clinical behavior, these four types of ML also formed a spectrum ranging from benign lesions (nevus type A and B) to malignant lesions (melanoma) with an intermediate category of melanocytic lesions of unknown malignant potential (atypical nevus).
Melanin-containing macrophages, called melanophages afterwards, were present in the dermis and the hypodermis and were associated with all types of ML. They were distinguished from melanocytes by their larger size and round to polygonal shape. When melanophagic infiltration was severe, ML were difficult to individualize. The intensity of melanophagic infiltration could vary among different samples from the same animal.
ML-A (classical blue nevus) (Figure 1A-F) were the predominant type of ML. Because of their small size (usually less than 200 μm) they were not grossly discernible. They were observed in mice from 21 days of age (Figure 1A-C). The smallest ML-A were composed of only few melanocytes. ML-A occurred in the dermis, usually in the vicinity of hair follicles. They were frequently stellate shaped due to ill-defined contours that blended in the surrounding dermis. Their cellularity was moderate as melanocytes were separated by collagen fibers. Melanocytes were small, spindle-shaped, heavily pigmented and had little cytoplasm (high nucleo-cytoplasmic ratio (NCR)). Their nucleus was small and poorly discernible due to abundant pigmentation. When visible, it harbored a fine and dusty chromatin and usually no nucleolus. Mitoses were absent. These morphological features supported a benign behavior (nevi).
ML-B (cellular blue nevus) (Figure 1G-I) were usually larger than ML-A but remained grossly indistinguishable. They were detected from 3 months onwards. They were well-demarcated, nodular to piriform and highly cellular lesions with densely packed melanocytes. Melanocytes were spindle-shaped and well pigmented but had more cytoplasm (moderate NCR) than in ML-A. Some epithelioid cells might be present. The nucleus, usually discernible, was round with a fine chromatin and a small nucleolus. Small capillaries could be present. These morphological features supported a benign behavior (nevi).
ML-C (atypical blue nevus) (Figure 2A-C) were usually grossly discernible and greater than 200 μm but very small ML-C also occurred. Grossly, they appeared as small black nodules or plaques. They mainly occurred in the upper dermis but large lesions extended in the deeper dermis. They were apparent in 5.5-month-old mice. They usually had ill-defined contours and frequently coalesced horizontally to form large plaques that lifted the epidermis. The overlying epidermis could be hyperplastic and form deep rete ridge. Epidermal invasion was rare. ML-C had high cellularity with densely packed melanocytes. Melanocytes were plump, spindle-shaped to epithelioid and had an abundant acidophilic cytoplasm (moderate to low NCR) that tended to be poorly pigmented in upper-dermis cells. The nucleus was round, large and frequently had a large acidophilic nucleolus. Atypias were moderate, and mitoses were rarely present (usually less than 1 mitosis per 10 high power fields (HPF) or per lesion). Small vessels were usually well discernible. Ulceration was rare. The malignant potential of ML-C was equivocal and difficult to determine based solely on morphological features.
ML-D (melanoma) (Figure 2D-I) were the less frequent but also the largest lesions. They first appeared in 7.5-month-old mice. They appeared as black, alopecic and frequently ulcerated nodules. They mostly arose from furry part of the skin and rarely on genitalia. They usually formed well-demarcated hypodermal nodules that occasionally encroached on the overlying dermis. These lesions were highly cellular with densely packed melanocytes that arranged in bundles or nests and frequently formed perivascular pseudorosettes. Artifactual clefts were frequently observed. Melanocytes were spindle to epithelioid with a moderate to abundant acidophilic cytoplasm (low to moderate NCR). Pigmentation was variable with the majority of lesions being poorly pigmented. Immunofluorescence for Melan-A and PEP-1 differentiation antigens performed on non-pigmented lesions or areas showed positive labeling confirming their melanocytic nature (Figure S2). The nucleus was round with a clear chromatin and an acidophilic nucleolus. Atypias were moderate to high and mitoses were commonly observed. Although their frequency was variable between lesions, ML-D usually displayed more than 5 mitoses per 10 HPF. More specifically, the presence of more than 1 mitosis in a HPF was virtually restricted to ML-D (Figure 2I). Necrosis and ulceration were frequent. Vascular invasion or emboli were almost never observed. These morphologic features were typical of a malignant melanocytic tumor (melanoma).
Table 1 summarizes histological features to be used for the diagnosis of cutaneous ML in Tyr::NRasQ61K; Cdkn2a−/−.
Because lymph nodes are the first metastatic site for cutaneous melanoma, they were systematically sampled (Figure 3 and Figure S1d-f). In young animals, some pigmented cells were observed and interpreted as interdigitating dendritic cells (Figure 3A-C). With age, lymph nodes progressively enlarged and became infiltrated by melanophages, resembling dermatopathic lymphadenopathy in humans (Figure 3D-F) (Ioachim, 2009). In mice diagnosed with cutaneous melanoma (ML-D), metastases could be observed in satellite lymph nodes (Figure 3G-L). Melanoma cells could be found in the lymph node subcapsular sinus, particularly in early metastases (Figure 3G, I). ML resembling cutaneous ML, ranging from ML-A to ML-D, were observed in lymph node (Figure 3E,F). Surprisingly, nearly 35% of these nodal ML occurred in the absence of concurrent cutaneous melanoma (ML-D). In these cases, melanocytic cells were hardly detected in the subcapsular sinus.
In young animals, melanocytes were observed in the leptomeninges, particularly in the rostral region of the brain, a well-known site for meningeal melanosis in mice (Figures S1 g-i and S3). From 7.5 months onwards, some animals developed cerebral ML. Grossly, they appeared as a unique ill-demarcated pigmented lesion in the rostral region that eventually distorted the brain due to a mass effect. On histopathological examination, these lesions were diagnosed as melanoma and closely resembled cutaneous melanoma (ML-D). Some pigmented areas and nodules were occasionally observed on the corresponding region on the calvarium and revealed to be extensions from cerebral melanoma. Animals with cerebral melanoma did not systematically have concurrent cutaneous melanoma. The lesions were considered to be primary cerebral melanoma.
In young animals, melanocytes were observed in the choroid layers of the eye where they formed a thin and regular layer (Figure S4). From 3 months onwards, some animals developed ocular ML resembling cutaneous ML with lesions ranging from ML-A to ML-D. ML-D were diagnosed as ocular melanomas and occurred from 7.5 months onwards. Animals with ocular melanoma did not systematically have concurrent cutaneous melanoma. The lesions were considered to be primary ocular melanocytic lesions.
After lymph nodes, lungs are considered to be the most common metastatic site for melanoma (Figures S1j-l and S5). On gross examination, melanoma metastases typically presented as multiple black spots (Figure S1j-l). On histopathological examination, metastases were frequently observed in the lungs and were typically associated with vessels. In one case, despite the absence of cutaneous gross features suggestive of malignancy, lung metastases were detected and histopathological analysis of the skin confirmed the presence of cutaneous ML-C/ML-D lesions.
The liver and the heart were infrequent sites for metastases with only 3 and 1 cases respectively.
Melanocytic lesions were observed in the spleen (2 cases), the harderian gland (1 case), and the epididymis (1 case) (Figure S6). Splenic and harderian lesions exhibited malignant features favoring a diagnosis of melanoma whereas the epididymal lesion had a benign aspect and resembled cutaneous ML-B. Although a metastatic nature could not been ruled out as concurrent cutaneous melanomas were observed in these mice, these lesions were considered to be primary rather than metastatic.
In Tyr::NRasQ61K; Cdkn2a−/− mice, a large spectrum of ML ranging from benign to malignant was observed in the skin. Four main types of lesions were identified and named as ML-A, ML-B, ML-C and ML-D, in a putative increasing order of malignancy. Indeed, ML-A and ML-B had a benign appearance and were considered to be the equivalent of the so-called melanocytic hyperplasia and nevi described previously (Ackermann et al., 2005). On the other hand, ML-D had typical malignant features and were considered to be equivalent to melanoma. ML-C appeared to be morphologically intermediate between nevi and melanoma, and were therefore difficult to categorize as benign or malignant. It is crucial to precisely identify this ML-C to correctly interpret changes in modified Tyr::NRasQ61K; Cdkn2a−/− mice. From ML-A to ML-D, there was a morphological progression characterized by both increase in size of lesions and cells, change in shape of cells from spindle to plump and epithelioid, increased atypias, mitotic index and vascularization, and a trend towards a loss of pigmentation. Furthermore, a chronological progression was also observed with ML-A being the first lesion to appear in young animals and ML-D being the ultimate lesion to develop in adults. We also noticed that the frequency of lesions decreased from ML-A to ML-D. All in all, these data strongly suggest that the sequence from ML-A to ML-D not only represents a morphological and chronological spectrum but also the multistep sequence of progression of ML in the Tyr::NRasQ61K mice. This is further supported by the presence of lesions with intermediate features that could not be assigned to a definitive type (transition forms).
Comparison with human pathology revealed that ML in this model had similar features to the blue nevus family although exact equivalence, in terms of pathogenesis, morphology and clinical behavior may not be complete. In this analogy, ML-A, ML-B, ML-C and ML-D would correspond to classical blue nevus, epithelioid blue nevus, atypical blue nevus and malignant blue nevus respectively. One of the most common locations of these tumors in humans is the scalp (Zembowicz and Phadke, 2011), reminiscent of fur in animals. Interestingly, atypical blue nevus is a particular entity for which biological behavior is difficult to predict and is part of lesions often referred to as melanocytic tumors of uncertain malignant potential (MELTUMP) (Barnhill and Gupta, 2009; Murali et al., 2009; Phadke and Zembowicz, 2011; Zembowicz and Phadke, 2011). In Tyr::CreERT2; Braf +/V600E and Tyr::CreERT2; KrasG12V mice models, blue nevi were also described (Dhomen et al., 2009; Milagre et al., 2010). As Tyr::NRasQ61K mice, these mice present skin hyperpigmentation in a C57BL/6 background. The tendency of these mice to develop blue nevi type lesions could be due to the predominance of dermal melanocytes. Here, we extend the comparison and provide evidence to link the lesions of Tyr::NRasQ61K; Cdkn2a−/− mice to the blue nevi family of lesions in humans. Because Tyr::NRasQ61K mice harbor numerous nevi with NRas mutations that can progress to melanoma, they were recently reported to be a model for giant congenital nevi (CGN) (Shakhova et al., 2012). Although this comparison is interesting because patients with CGN can develop neuromelanosis (Alikhan et al., 2012) which is reminiscent of the primary cerebral ML observed in these mice, our histological analysis showed that nevi in CGN are morphologically distinct from the ML observed in Tyr::NRasQ61K mice.
Mice lacking Cdkn2a are reported to develop sarcomas and lymphomas with a rate of 70%, which may cause diagnostic difficulties (Serrano et al., 1996). In our colony however, only 4 out of 26 (15%) Tyr::NRasQ61K; Cdkn2a−/− mice were diagnosed with non-melanocytic tumors (Data S1) suggesting that additional genes may cooperate with Cdkn2a for tumor suppression (Takeuchi et al., 2010). Non-melanocytic tumors can be differentiated from ML by their morphological and immunohistochemical characteristics. The distinction is particularly important with ML-D that tend to be poorly pigmented.
Unexpected results came from the histopathological examination of lymph nodes. Besides typical melanoma metastasis, lesions resembling cutaneous ML and ranging from ML-A-like to ML-D-like were observed in some lymph nodes without associated cutaneous melanoma. We propose different hypotheses to explain these observations: (i) primary nodal ML could develop in the Tyr::NRasQ61K model as for other extra cutaneous site (see below); (ii) other ML than ML-D, especially ML-C, could have malignant potential and produce metastasis; (iii) a combination of these hypotheses.
Primary cerebral melanomas were diagnosed. A metastatic nature is considered unlikely because (i) lesions invariably developed in the rostral brain, a typical site for meningeal melanosis in C57BL/6 mice; this specific distribution was previously reported (Lindsay et al., 2011); (ii) unlike metastases, lesions were large and unique rather than small and multifocal; (iii) unlike metastases, lesions appeared to originate from the leptomeninges rather than from vessels at the interface between white and grey matters (Brat et al., 1999; Das et al., 2010; Kusters-Vandevelde et al., 2010); 4) lesions were observed in animals without cutaneous melanoma.
Similarly, primary ocular ML, including nevi and melanomas were frequently diagnosed and originated from the choroid where melanocytes normally exist. Infrequently, ML were diagnosed in the spleen, the harderian gland and the epididymis in animals with concurrent cutaneous melanomas (ML-D). Interestingly, a potential primary nature of the lesions could not be ruled out since ectopic melanocytes are present in C57BL/6 mice in the spleen, the heart or the harderian gland (Percy and Barthold, 2007; Yajima and Larue, 2008) as in humans (Plonka et al., 2009). The results suggest that, because extra-cutaneous melanocytes are common in C57BL/6 mice and because all melanocytes harbor the NRasQ61K activating mutation in the Tyr::NRasQ61K mice, primary ML including melanomas can develop in non-cutaneous sites. Although it is unclear whether ectopic melanocytes are present or not in lymph nodes, we believe that the existence of primary nodal ML should be considered in the Tyr::NRasQ61K model. Interestingly, intracapsular primary nodal melanocytic nevi have been described in humans, though they were not reported to progress to melanoma as we observed in the Tyr::NRasQ61K model (Dohse and Ferringer, 2010; Holt et al., 2004; Misago et al., 2008).
Accurate histopathological phenotyping of mice models is a challenge (Sellers and Ward, 2012). Accordingly, the Tyr::NRasQ61K; Cdkn2a−/− model appeared to be much more complex than expected. With at least four types of cutaneous ML identified, this model offers opportunity to study the steps of melanomagenesis. The presence of extra-cutaneous melanocytes harbouring the same mutations as cutaneous melanocytes is responsible for the development of primary extra-cutaneous ML that co-exist with primary cutaneous ML and metastases. This feature should not be underestimated and should prompt to practice thorough necropsies. As a typical site for melanophagic infiltration and metastases, and a putative site for primary ML, lymph nodes appear to be the most challenging non-cutaneous site to evaluate. Histopathological evaluation of lymph node should be systematic and a metastatic status should not be assigned based solely on gross features.
We hope that the proposed classification and atlas will be the basis for a common language between pathologists and researchers of the melanoma community working with Tyr::NRASQ61K; Cdkn2a−/− transgenic mice. The present classification is intended to evolve with the improvement of the comprehension of the molecular mechanisms of melanomagenesis.
We thank C. Koënen for mice care, as well as A. Champeix, R. Nkosi and P. Wattier for histological technical assistance, M. Serrano for providing Cdkn2a−/+ mice, L. Larue for the backcrosses in C57BL/6J background and V. Hearing for providing the Tyrp1 (PEP-1) antibody. This work was supported by Institut National de la Recherche Agronomique, Agence Nationale de la Recherche Emergence Bio and Association pour la Recherche contre le Cancer grants. CC was granted by Allocation de Recherche MENRT from the French Ministry of Research (2009–2012).
- 2005). Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65, 4005–4011. , , , , , and (
- 2012). Congenital melanocytic nevi: where are we now? Part I. Clinical presentation, epidemiology, pathogenesis, histology, malignant transformation, and neurocutaneous melanosis. J. Am. Acad. Dermatol. 67, 495 e1–495 e17; quiz 512-4. , , and (
- 2009). Unusual variants of malignant melanoma. Clin. Dermatol. 27, 564–587. , and (
- 1999). Primary melanocytic neoplasms of the central nervous systems. Am. J. Surg. Pathol. 23, 745–754. , , , and (
- 2010). Primary malignant melanoma at unusual sites: an institutional experience with review of literature. Melanoma Res. 20, 233–239. , , , , , , and (
- 2011). Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell. Melanoma. Res. 24, 666–672. , , , , , , , and (
- 2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294–303. , , , , , , , , and (
- 2010). Nodal blue nevus: a pitfall in lymph node biopsies. J. Cutan. Pathol. 37, 102–104. , and (
- 2011). Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin. Cancer Res. 17, 229–235. , , et al. (
- 1998). p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J. Cutan. Pathol. 25, 291–296. , , , , , and (
- 2005). Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin. Cancer Res. 11, 2991–2997. , , , , and (
- 2004). Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi. Am. J. Clin. Pathol. 121, 58–63. , , , , , , and (
- 2009). Dermatophatic lymphadenopathy. In Lymph node pathology, H.L., Ioachim, and L.J., Medeiros, eds. (Philadelphia: Lippincott & Williams & Williams), pp. 223–226. (
- 2010). Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol. 119, 317–323. , , , , , , , , and (
- 2011). Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol. 164, 776–784. , , and (
- 2011). P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat. Commun. 2, 555. , , et al. (
- 2010). A mouse model of melanoma driven by oncogenic KRAS. Cancer Res. 70, 5549–5557. , , , , , , and (
- 2008). Cellular blue nevus with nevus cells in a sentinel lymph node. Eur. J. Dermatol. 18, 586–589. , , , , , and (
- 2009). Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls. Adv. Anat. Pathol. 16, 365–382. , , and (
- 2007). Introduction. In The mouse, B.P., Professional, ed. (Ames, IA: Blackwell Publishing), pp. 4–6. , and (
- 2011). Blue nevi and related tumors. Clin. Lab. Med. 31, 345–358. , and (
- 2009). What are melanocytes really doing all day long..? Exp. Dermatol. 18, 799–819. , , et al. (
- 2012). Toward a better understanding of mouse models of disease. Vet. Pathol. 49, 4. , and (
- 1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27–37. , , , , , and (
- 2012). Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat. Cell Biol. 14, 882–890. , , et al. (
- 2010). Intrinsic cooperation between p16INK4a and p21Waf1/Cip1 in the onset of cellular senescence and tumor suppression in vivo. Cancer Res. 70, 9381–9390. , , et al. (
- 2011). Modelling melanoma in mice. Pigment Cell. Melanoma. Res. 24, 1158–1176. , , , and (
- 2008). The location of heart melanocytes is specified and the level of pigmentation in the heart may correlate with coat color. Pigment Cell. Melanoma. Res. 21, 471–476. , and (
- 2011). Blue nevi and variants: an update. Arch. Pathol. Lab. Med. 135, 327–336. , and (
|pcmr12115-sup-0002-FigS1.tif||image/tif||19409K||Figure S1. Gross features of ML.|
|pcmr12115-sup-0003-FigS2.tif||image/tif||10087K||Figure S2. Expression of melanocytic markers in non-pigmented ML-D.|
|pcmr12115-sup-0004-FigS3.tif||image/tif||9989K||Figure S3. Histopathological features of cerebral ML.|
|pcmr12115-sup-0005-FigS4.tif||image/tif||28828K||Figure S4. Histopathological features of ocular ML.|
|pcmr12115-sup-0006-FigS5.tif||image/tif||5269K||Figure S5. Pulmonary metastatic melanoma.|
|pcmr12115-sup-0007-FigS6.tif||image/tif||9935K||Figure S6. Infrequent sites for melanocytic lesions: Epididymis.|
Table S1. Frequency of the most common ML encountered in Tyr::NRasQ61K; Cdkn2a−/− transgenic mice.
Data S1. Materials and methods, supplementary data and figure legends.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.